Loading
STAT5 is the messenger that carries growth signals from FLT3, JAK2 and BCR::ABL1 into the nucleus and switches on survival genes in leukaemia cells. No drug hits STAT5 directly yet; the FLT3 and ABL inhibitors work by cutting off the signal above it. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
The JAK-STAT pathway record lists STAT5 as the STAT of leukaemias, alongside STAT3 as the hub of IL-6-driven survival. Constitutive STAT5 signalling is the readout of FLT3, JAK2, MPL and BCR::ABL1 activity in the corpus mechanism steps, and no direct STAT5 inhibitor is recorded.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"STAT5" OR ABSTRACT:"STAT5" OR TITLE:"STAT5A, STAT5B" OR ABSTRACT:"STAT5A, STAT5B" OR TITLE:"STAT5A" OR ABSTRACT:"STAT5A" OR TITLE:"STAT5B" OR ABSTRACT:"STAT5B" OR TITLE:"signal transducer and activator of transcription 5" OR ABSTRACT:"signal transducer and activator of transcription 5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAT5 (STAT5A, STAT5B), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/stat5.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/stat5.json. Licence CC BY-NC 4.0.